HEAL Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Restart Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.04 |
| 52 Week High | CA$0.13 |
| 52 Week Low | CA$0.015 |
| Beta | 0.63 |
| 11 Month Change | 60.00% |
| 3 Month Change | -20.00% |
| 1 Year Change | -68.00% |
| 33 Year Change | -89.33% |
| 5 Year Change | -96.67% |
| Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
| HEAL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 33.3% | -2.9% | 2.2% |
| 1Y | -68.0% | -5.4% | 23.4% |
Return vs Industry: HEAL underperformed the Canadian Biotechs industry which returned -8.6% over the past year.
Return vs Market: HEAL underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
| HEAL volatility | |
|---|---|
| HEAL Average Weekly Movement | 54.1% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: HEAL's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: HEAL's weekly volatility (54%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Steve Loutskou | www.restartlife.co |
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024.
Restart Life Sciences Corp. Fundamentals Summary
| HEAL fundamental statistics | |
|---|---|
| Market cap | CA$1.19m |
| Earnings (TTM) | -CA$628.58k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs HEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HEAL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$628.58k |
| Earnings | -CA$628.58k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.7% |
How did HEAL perform over the long term?
See historical performance and comparison